Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Rodriguez-Duque JC
  • Calleja JL
  • Hernández-Conde M
  • Rivas-Rivas C
  • Vera MI
  • García-Blanco A
  • Lopez-Montejo L
  • Fernández-Lamas T
  • Rasines L
  • Frias Y



BACKGROUND AND AIM: There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). We aimed to determine MAFLD prevalence and risk factors in IBD patients. METHODS: Cross-sectional, case-control study that included all consecutive IBD patients treated at two different university hospitals. Controls were subjects randomly selected from the general population and matched by age, sex, type 2 diabetes (T2D) status and BMI in a 1:2 ratio. MAFLD was confirmed by controlled attenuation parameter (CAP). Liver biopsies were collected when MAFLD with significant liver fibrosis was suspected. Additionally, age- and fibrosis stage-paired non-IBD patients with biopsy-proven MAFLD served as a secondary control group. RESULTS: 831 IBD patients and 1718 controls were included. The prevalence of MAFLD and advanced liver fibrosis (TE = 9.7 kPa) was 42.00% and 9.50%, respectively, in IBD patients and 32.77% and 2.31%, respectively, in the general population (p < 0.001). A diagnosis of IBD was an independent predictor of MAFLD (adjusted OR 1.99; p < 0.001) and an independent risk factor for advanced liver fibrosis (adjusted OR 5.55; p < 0.001). Liver biopsies were obtained from 40 IBD patients; MAFLD was confirmed in all cases and fibrosis of any degree was confirmed in 25/40 (62.5%) cases. BMI and T2D prevalence were significantly lower in IBD-MAFLD patients than in severity-paired patients with biopsy-proven MAFLD. CONCLUSIONS: MAFLD and liver fibrosis are particularly prevalent in IBD patients, regardless of the influence of classic metabolic risk factors.

Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Datos de la publicación

1542-3565, 1542-7714



Citas Recibidas en Web of Science: 28


  • No hay documentos


Filiaciones mostrar / ocultar


  • MAFLD; inflammatory bowel disease; liver fibrosis; metabolic syndrome

Campos de estudio